These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30642922)

  • 21. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
    Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
    J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.
    Morgan A; Cofer C; Stevens DL
    Future Microbiol; 2009 Mar; 4(2):131-44. PubMed ID: 19257839
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Scangarella-Oman NE; Ingraham KA; Tiffany CA; Tomsho L; Van Horn SF; Mayhew DN; Perry CR; Ashton TC; Dumont EF; Huang J; Brown JR; Miller LA
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iclaprim activity against wild-type and corresponding thymidine kinase-deficient Staphylococcus aureus in a mouse protection model.
    Huang DB; Park JH; Murphy TM
    Eur J Clin Microbiol Infect Dis; 2019 Feb; 38(2):409-412. PubMed ID: 30483998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
    Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN
    Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iclaprim, a dihydrofolate reductase inhibitor antibiotic in Phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety.
    Huang DB; Dryden M
    Future Microbiol; 2018 Jul; 13():957-969. PubMed ID: 29742926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    Surg Infect (Larchmt); 2016 Aug; 17(4):443-7. PubMed ID: 26990170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.
    Lodise TP; Bosso J; Kelly C; Williams PJ; Lane JR; Huang DB
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.
    Sader HS; Biedenbach DJ; Paukner S; Ivezic-Schoenfeld Z; Jones RN
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1619-23. PubMed ID: 22232289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).
    Holland TL; O'Riordan W; McManus A; Shin E; Borghei A; File TM; Wilcox MH; Torres A; Dryden M; Lodise T; Oguri T; Corey GR; McLeroth P; Shukla R; Huang DB
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
    Soriano A; Rossolini GM; Pea F
    Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465
    [No Abstract]   [Full Text] [Related]  

  • 33. Iclaprim.
    Kohlhoff SA; Sharma R
    Expert Opin Investig Drugs; 2007 Sep; 16(9):1441-8. PubMed ID: 17714029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
    Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
    Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro bactericidal activity of iclaprim in human plasma.
    Laue H; Valensise T; Seguin A; Lociuro S; Islam K; Hawser S
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4542-4. PubMed ID: 19651909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012).
    Flamm RK; Farrell DJ; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):449-56. PubMed ID: 24529941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program.
    Farrell DJ; Liverman LC; Biedenbach DJ; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):415-20. PubMed ID: 21982563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Jorgenson MR; DePestel DD; Carver PL
    Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe.
    Pfaller MA; Rhomberg PR; Huband MD; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
    Esposito S; Noviello S; Leone S
    Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.